A Study Of Intraocular Inflammation Following Intravitreal Anti-VEGF/anti-angiopoietin 2 Injection

Overview

About this study

The purpose of this study is to improve the safety and personalization of intravitreal therapy. Our overall objective is to identify subclinical cases that may predict future adverse events and establish evidence-based monitoring strategies. Our central hypothesis is that the prevalence of subclinical IOI is higher than previously recognized, that distinct patient and treatment factors confer differential risk, and that subclinical IOI is a biomarker for subsequent severe IOI. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age >18

  • Currently receiving IVT anti-VEGF/anti-ang-2 in the Mayo Clinic Rochester injection clinic.

Exclusion Criteria: 

  • Age < 18

  • Home address >20 minutes away from the Mayo Clinic in Rochester, Minnesota.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/15/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Brittni Scruggs, M.D., Ph.D.

Open for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions